{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:00:10Z","timestamp":1773504010091,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation in China","doi-asserted-by":"crossref","award":["81503137"],"award-info":[{"award-number":["81503137"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00228-020-03034-4","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T19:02:26Z","timestamp":1605121346000},"page":"595-605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Predicting the presence and mechanism of busulfan drug-drug interactions in hematopoietic stem cell transplantation using pharmacokinetic interaction network\u2013based molecular structure similarity and network pharmacology"],"prefix":"10.1007","volume":"77","author":[{"given":"Chenxia","family":"Hao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lining","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2711-4791","authenticated-orcid":false,"given":"Wanhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"issue":"3","key":"3034_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4067\/S0716-97602012000300012","volume":"45","author":"F Barriga","year":"2012","unstructured":"Barriga F, Ram\u00edrez P, Wietstruck A, Rojas N (2012) Hematopoietic stem cell transplantation: clinical use and perspectives. Biol Res 45(3):307\u2013316. https:\/\/doi.org\/10.4067\/S0716-97602012000300012","journal-title":"Biol Res"},{"issue":"5","key":"3034_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.bbmt.2008.12.489","volume":"15","author":"SO Ciurea","year":"2009","unstructured":"Ciurea SO, Andersson BS (2009) Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(5):523\u2013536. https:\/\/doi.org\/10.1016\/j.bbmt.2008.12.489","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3034_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/FTD.0b013e3182a04fc7","volume":"36","author":"M Ansari","year":"2014","unstructured":"Ansari M, Th\u00e9oret Y, Rezgui MA, Peters C, Mezziani S, Desjean C, Vachon MF, Champagne MA, Duval M, Krajinovic M, Bittencourt H (2014) Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. Ther Drug Monit 36(1):93\u201399. https:\/\/doi.org\/10.1097\/FTD.0b013e3182a04fc7","journal-title":"Ther Drug Monit"},{"issue":"9","key":"3034_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","volume":"8","author":"BS Andersson","year":"2002","unstructured":"Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE (2002) Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 8(9):477\u2013485. https:\/\/doi.org\/10.1053\/bbmt.2002.v8.pm12374452","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"3034_CR5","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.bbmt.2018.06.034","volume":"24","author":"KT Hong","year":"2018","unstructured":"Hong KT, Kang HJ, Choi JY, Hong CR, Cheon JE, Park JD, Park KD, Song SH, Yu KS, Jang IJ, Shin HY (2018) Favorable outcome of post-transplantation cyclophosphamide haploidentical peripheral blood stem cell transplantation with targeted busulfan-based myeloablative conditioning using intensive pharmacokinetic monitoring in pediatric patients. Biol Blood Marrow Transplant 24(11):2239\u20132244. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.034","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3034_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/1078155217729745","volume":"25","author":"K Sweiss","year":"2019","unstructured":"Sweiss K, Quigley JG, Oh A, Lee J, Ye R, Rondelli D, Patel P (2019) A novel drug interaction between busulfan and blinatumomab. J Oncol Pharm Pract 25(1):226\u2013228. https:\/\/doi.org\/10.1177\/1078155217729745","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"3034_CR7","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/sj.bmt.1702377","volume":"25","author":"M Hassan","year":"2000","unstructured":"Hassan M, Ljungman P, Ringd\u00e9n O, Hassan Z, Oberg G, Nilsson C, B\u00e9kassy A, Bielenstein M, Abdel-Rehim M, Geor\u00e9n S et al (2000) The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 25(9):915\u2013924. https:\/\/doi.org\/10.1038\/sj.bmt.1702377","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"3034_CR8","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/17425255.2017.1360277","volume":"13","author":"AL Myers","year":"2017","unstructured":"Myers AL, Kawedia JD, Champlin RE, Kramer MA, Nieto Y, Ghose R, Andersson BS (2017) Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opin Drug Metab Toxicol 13(9):901\u2013923. https:\/\/doi.org\/10.1080\/17425255.2017.1360277","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"3034_CR9","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1136\/amiajnl-2012-000935","volume":"19","author":"S Vilar","year":"2012","unstructured":"Vilar S, Harpaz R, Uriarte E, Santana L, Rabadan R, Friedman C (2012) Drug-drug interaction through molecular structure similarity analysis. J Am Med Inform Assoc 19(6):1066\u20131074. https:\/\/doi.org\/10.1136\/amiajnl-2012-000935","journal-title":"J Am Med Inform Assoc"},{"issue":"2","key":"3034_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00280-014-2657-8","volume":"75","author":"DD Trevisan","year":"2015","unstructured":"Trevisan DD, Silva JB, Oliveira HC, Secoli SR, Lima MH (2015) Prevalence and clinical significance of potential drug-drug interaction in hematopoietic stem cell transplantation. Cancer Chemother Pharmacol 75(2):393\u2013400. https:\/\/doi.org\/10.1007\/s00280-014-2657-8","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"3034_CR11","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s11096-011-9574-2","volume":"33","author":"RB Guastaldi","year":"2011","unstructured":"Guastaldi RB, Reis AM, Figueras A, Secoli SR (2011) Prevalence of potential drug-drug interactions in bone marrow transplant patients. Int J Clin Pharm 33(6):1002\u20131009. https:\/\/doi.org\/10.1007\/s11096-011-9574-2","journal-title":"Int J Clin Pharm"},{"key":"3034_CR12","doi-asserted-by":"publisher","unstructured":"Carreras E, Dufour C, Mohty M, Kr\u00f6ger N (2019) The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. Springer. https:\/\/doi.org\/10.1007\/978-3-030-02278-5","DOI":"10.1007\/978-3-030-02278-5"},{"issue":"2","key":"3034_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/sj.bmt.1704316","volume":"33","author":"HL Leather","year":"2004","unstructured":"Leather HL (2004) Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant 33(2):137\u2013152. https:\/\/doi.org\/10.1038\/sj.bmt.1704316","journal-title":"Bone Marrow Transplant"},{"key":"3034_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13321-017-0200-8","volume":"9","author":"T Takeda","year":"2017","unstructured":"Takeda T, Hao M, Cheng T, Bryant SH, Wang Y (2017) Predicting drug-drug interactions through drug structural similarities and interaction networks incorporating pharmacokinetics and pharmacodynamics knowledge. J Cheminform 9:16. https:\/\/doi.org\/10.1186\/s13321-017-0200-8","journal-title":"J Cheminform"},{"issue":"4","key":"3034_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/10428194.2017.1361027","volume":"59","author":"V Dhere","year":"2018","unstructured":"Dhere V, Edelman S, Waller EK, Langston A, Graiser M, Connolly EC, Switchenko JM, Esiashvili N, Khan MK (2018) Myeloablative busulfan\/cytoxan conditioning versus reduced-intensity fludarabine\/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia. Leuk Lymphoma 59(4):837\u2013843. https:\/\/doi.org\/10.1080\/10428194.2017.1361027","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"3034_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","volume":"14","author":"BS Andersson","year":"2008","unstructured":"Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE (2008) Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML\/MDS. Biol Blood Marrow Transplant 14(6):672\u2013684. https:\/\/doi.org\/10.1016\/j.bbmt.2008.03.009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"3034_CR17","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s11095-016-1927-z","volume":"33","author":"J Bouligand","year":"2016","unstructured":"Bouligand J, Richard C, Valteau-Couanet D, Orear C, Mercier L, Kessari R, Simonnard N, Munier F, Daudigeos-Dubus E, Tou B, Opolon P, Deroussent A, Paci A, Vassal G (2016) Iron overload exacerbates busulfan-melphalan toxicity through a pharmacodynamic interaction in mice. Pharm Res 33(8):1913\u20131922. https:\/\/doi.org\/10.1007\/s11095-016-1927-z","journal-title":"Pharm Res"},{"issue":"2","key":"3034_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.bbmt.2011.06.013","volume":"18","author":"RF Yeh","year":"2012","unstructured":"Yeh RF, Pawlikowski MA, Blough DK, McDonald GB, O\u2019Donnell PV, Rezvani A, Deeg HJ, McCune JS (2012) Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 18(2):265\u2013272. https:\/\/doi.org\/10.1016\/j.bbmt.2011.06.013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"3034_CR19","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.bbmt.2011.12.584","volume":"18","author":"JB Perkins","year":"2012","unstructured":"Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, Kharfan-Dabaja MA, Tomblyn MR, Sullivan DM, Pidala JA, Field TL (2012) Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 18(7):1099\u20131107. https:\/\/doi.org\/10.1016\/j.bbmt.2011.12.584","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"3034_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/sj.bmt.1705565","volume":"39","author":"M Bonin","year":"2007","unstructured":"Bonin M, Pursche S, Bergeman T, Leopold T, Illmer T, Ehninger G, Schleyer E, Bornhauser M (2007) F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. Bone Marrow Transplant 39(4):201\u2013206. https:\/\/doi.org\/10.1038\/sj.bmt.1705565","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"3034_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/sj.bmt.1703896","volume":"31","author":"C Nilsson","year":"2003","unstructured":"Nilsson C, Aschan J, Hentschke P, Ringden O, Ljungman P, Hassan M (2003) The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 31(6):429\u2013435. https:\/\/doi.org\/10.1038\/sj.bmt.1703896","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"3034_CR22","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.bbmt.2011.11.029","volume":"18","author":"B Glotzbecker","year":"2012","unstructured":"Glotzbecker B, Duncan C, Alyea E 3rd, Campbell B, Soiffer R (2012) Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol Blood Marrow Transplant 18(7):989\u20131006. https:\/\/doi.org\/10.1016\/j.bbmt.2011.11.029","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4A","key":"3034_CR23","first-page":"2083","volume":"16","author":"I Buggia","year":"1996","unstructured":"Buggia I, Zecca M, Alessandrino EP, Locatelli F, Rosti G, Bosi A, Pession A, Rotoli B, Majolino I, Dallorso A, Regazzi MB (1996) Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. Anticancer Res 16(4A):2083\u20132088","journal-title":"Anticancer Res"},{"issue":"5","key":"3034_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.apsb.2016.07.002","volume":"6","author":"CT Brewer","year":"2016","unstructured":"Brewer CT, Chen T (2016) PXR variants: the impact on drug metabolism and therapeutic responses. Acta Pharm Sin B 6(5):441\u2013449. https:\/\/doi.org\/10.1016\/j.apsb.2016.07.002","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"3034_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/17425255.2019.1552256","volume":"15","author":"A Pej\u010di\u0107","year":"2018","unstructured":"Pej\u010di\u0107 A, Jankovi\u0107 SM, Opan\u010dina V, Babi\u0107 G, Milosavljevi\u0107 M (2018) Drug\u2013drug interactions in patients receiving hematopoietic stem cell transplantation. Expert Opin Drug Metab Toxicol 15(1):49\u201359. https:\/\/doi.org\/10.1080\/17425255.2019.1552256","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"3034_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/tpj.2013.38","volume":"14","author":"CR Uppugunduri","year":"2014","unstructured":"Uppugunduri CR, Rezgui MA, Diaz PH, Tyagi AK, Rousseau J, Daali Y, Duval M, Bittencourt H, Krajinovic M, Ansari M (2014) The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation. Pharmacogenomics J 14(3):263\u2013271. https:\/\/doi.org\/10.1038\/tpj.2013.38","journal-title":"Pharmacogenomics J"},{"issue":"1\u20132","key":"3034_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.cca.2005.12.011","volume":"368","author":"M Kusama","year":"2006","unstructured":"Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y, Iga T (2006) Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta 368(1\u20132):93\u201398. https:\/\/doi.org\/10.1016\/j.cca.2005.12.011","journal-title":"Clin Chim Acta"},{"issue":"1","key":"3034_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/s0300-483x(03)00247-6","volume":"192","author":"M Pirmohamed","year":"2003","unstructured":"Pirmohamed M (2003) Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 192(1):23\u201332. https:\/\/doi.org\/10.1016\/s0300-483x(03)00247-6","journal-title":"Toxicology"},{"issue":"7","key":"3034_CR29","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2217\/pgs-2017-0194","volume":"18","author":"MA Bahar","year":"2017","unstructured":"Bahar MA, Setiawan D, Hak E, Wilffert B (2017) Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. Pharmacogenomics 18(7):701\u2013739. https:\/\/doi.org\/10.2217\/pgs-2017-0194","journal-title":"Pharmacogenomics"},{"issue":"2","key":"3034_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12281-015-0219-0","volume":"9","author":"B Moriyama","year":"2015","unstructured":"Moriyama B, Kadri S, Henning SA, Danner RL, Walsh TJ, Penzak SR (2015) Therapeutic drug monitoring and genotypic screening in the clinical use of voriconazole. Curr Fungal Infect Rep 9(2):74\u201387. https:\/\/doi.org\/10.1007\/s12281-015-0219-0","journal-title":"Curr Fungal Infect Rep"},{"issue":"6","key":"3034_CR31","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00432-017-2357-y","volume":"143","author":"S Beata","year":"2017","unstructured":"Beata S, Donata UK, Jaroslaw D, Tomasz W, Anna WH (2017) Influence of CYP2C19*2\/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report. J Cancer Res Clin Oncol 143(6):1103\u20131106. https:\/\/doi.org\/10.1007\/s00432-017-2357-y","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"3034_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.retram.2020.02.001","volume":"68","author":"NK Zgheib","year":"2020","unstructured":"Zgheib NK, Alameddine R, Massoud R, Nasr R, Zahreddine A, El Cheikh J, Mahfouz R, Bazarbachi A (2020) The role of candidate genetic polymorphisms in the interaction between voriconazole and cyclosporine in patients undergoing allogeneic hematopoietic cell transplantation: an explorative study. Curr Res Transl Med 68(2):51\u201358. https:\/\/doi.org\/10.1016\/j.retram.2020.02.001","journal-title":"Curr Res Transl Med"},{"issue":"9","key":"3034_CR33","first-page":"1015","volume":"24","author":"M Czerwinski","year":"1996","unstructured":"Czerwinski M, Gibbs JP, Slattery JT (1996) Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 24(9):1015\u20131019","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"3034_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/BF03189864","volume":"12","author":"M Hassan","year":"1987","unstructured":"Hassan M, Ehrsson H (1987) Metabolism of 14C-busulfan in isolated perfused rat liver. Eur J Drug Metab Pharmacokinet 12(1):71\u201376. https:\/\/doi.org\/10.1007\/BF03189864","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"3034_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2217\/pgs.12.185","volume":"14","author":"M Hassan","year":"2013","unstructured":"Hassan M, Andersson BS (2013) Role of pharmacogenetics in busulfan\/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. Pharmacogenomics 14(1):75\u201387. https:\/\/doi.org\/10.2217\/pgs.12.185","journal-title":"Pharmacogenomics"},{"issue":"5","key":"3034_CR36","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/sj.clpt.6100336","volume":"83","author":"A K\u00fchne","year":"2008","unstructured":"K\u00fchne A, Sezer O, Heider U, Meineke I, Muhlke S, Niere W, Overbeck T, Hohloch K, Tr\u00fcmper L, Brockm\u00f6ller J, Kaiser R (2008) Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. Clin Pharmacol Ther 83(5):749\u2013757. https:\/\/doi.org\/10.1038\/sj.clpt.6100336","journal-title":"Clin Pharmacol Ther"},{"issue":"26","key":"3034_CR37","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1182\/blood-2013-07-516666","volume":"122","author":"GG Johnson","year":"2013","unstructured":"Johnson GG, Lin K, Cox TF, Oates M, Sibson DR, Eccles R, Lloyd B, Gardiner LJ, Carr DF, Pirmohamed M, Strefford JC, Oscier DG, Gonzalez de Castro D, Else M, Catovsky D, Pettitt AR (2013) CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. Blood 122(26):4253\u20134258. https:\/\/doi.org\/10.1182\/blood-2013-07-516666","journal-title":"Blood"},{"issue":"12","key":"3034_CR38","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.bcp.2007.03.012","volume":"73","author":"N Murayama","year":"2007","unstructured":"Murayama N, Imai N, Nakane T, Shimizu M, Yamazaki H (2007) Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol 73(12):2020\u20132026. https:\/\/doi.org\/10.1016\/j.bcp.2007.03.012","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"3034_CR39","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1177\/0091270006293753","volume":"46","author":"RL Walsky","year":"2006","unstructured":"Walsky RL, Astuccio AV, Obach RS (2006) Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol 46(12):1426\u20131438. https:\/\/doi.org\/10.1177\/0091270006293753","journal-title":"J Clin Pharmacol"},{"issue":"23","key":"3034_CR40","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.3748\/wjg.15.2817","volume":"15","author":"G Tarantino","year":"2009","unstructured":"Tarantino G, Di Minno MN, Capone D (2009) Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol 15(23):2817\u20132833. https:\/\/doi.org\/10.3748\/wjg.15.2817","journal-title":"World J Gastroenterol"},{"issue":"8","key":"3034_CR41","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1007\/s11095-016-2091-1","volume":"34","author":"AK Daly","year":"2017","unstructured":"Daly AK (2017) Are polymorphisms in genes relevant to drug disposition predictors of susceptibility to drug-induced liver injury? Pharm Res 34(8):1564\u20131569. https:\/\/doi.org\/10.1007\/s11095-016-2091-1","journal-title":"Pharm Res"},{"issue":"9","key":"3034_CR42","doi-asserted-by":"publisher","first-page":"956","DOI":"10.2174\/138920009790711805","volume":"10","author":"RJ Andrade","year":"2009","unstructured":"Andrade RJ, Ag\u00fandez JA, Lucena MI, Mart\u00ednez C, Cueto R, Garc\u00eda-Mart\u00edn E (2009) Pharmacogenomics in drug induced liver injury. Curr Drug Metab 10(9):956\u2013970. https:\/\/doi.org\/10.2174\/138920009790711805","journal-title":"Curr Drug Metab"},{"issue":"5","key":"3034_CR43","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1039\/c8mt00361k","volume":"11","author":"Y Li","year":"2019","unstructured":"Li Y, Lin N, Ji X, Mai J, Li Q (2019) Organotin compound DBDCT induces CYP3A suppression through NF-\u03baB-mediated repression of PXR activity. Metallomics 11(5):936\u2013948. https:\/\/doi.org\/10.1039\/c8mt00361k","journal-title":"Metallomics"},{"issue":"1","key":"3034_CR44","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3324\/haematol.2013.089888","volume":"99","author":"F Bonifazi","year":"2014","unstructured":"Bonifazi F, Storci G, Bandini G, Marasco E, Dan E, Zani E, Albani F, Bertoni S, Bontadini A, De Carolis S et al (2014) Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation. Haematologica 99(1):172\u2013179. https:\/\/doi.org\/10.3324\/haematol.2013.089888","journal-title":"Haematologica"},{"issue":"4","key":"3034_CR45","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1042\/BST20150014","volume":"43","author":"JD Wardyn","year":"2015","unstructured":"Wardyn JD, Ponsford AH, Sanderson CM (2015) Dissecting molecular cross-talk between Nrf2 and NF-kappaB response pathways. Biochem Soc Trans 43(4):621\u2013626. https:\/\/doi.org\/10.1042\/BST20150014","journal-title":"Biochem Soc Trans"},{"issue":"10","key":"3034_CR46","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2174\/1389200216666150401110610","volume":"15","author":"S Shi","year":"2014","unstructured":"Shi S, Li Y (2014) Interplay of drug-metabolizing enzymes and transporters in drug absorption and disposition. Curr Drug Metab 15(10):915\u2013941. https:\/\/doi.org\/10.2174\/1389200216666150401110610","journal-title":"Curr Drug Metab"},{"key":"3034_CR47","doi-asserted-by":"publisher","unstructured":"Guilcher GMT, Shah R, Shenoy S (2018) Principles of alemtuzumab immunoablation in hematopoietic cell transplantation for non-malignant diseases in children: a review. Pediatr Transplant 22(2). https:\/\/doi.org\/10.1111\/petr.13142","DOI":"10.1111\/petr.13142"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03034-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-020-03034-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03034-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T14:14:48Z","timestamp":1614953688000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-020-03034-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["3034"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-03034-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]},"assertion":[{"value":"21 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}